New Webinar: Coding, Coverage, and Reimbursement for Beyfortus® (nirsevimab-alip)
We are happy to share that Sanofi is offering a complimentary 40-minute webinar on coding, coverage, and reimbursement for Beyfortus® (nirsevimab-alip). Sanofi believes that your attendance at this webinar will leave you well informed and better prepared to begin coding and billing for Beyfortus.
This webinar will cover several important topics, including:
Beyfortus coverage information for most major health plans
A review of the national reimbursement landscape
The recently released administration codes specific to Beyfortus
How to code & bill for Beyfortus
Considerations for setting charge amounts
Resources Sanofi offers to assist you with coverage, coding, and billing for Beyfortus
Please review the invitation below and register right away for this complimentary webinar. There are 9 live sessions to choose from, each include a presentation followed by a live Q&A. Registration will only take a few moments and you will then receive a non-shareable link to use to join the program. You will also receive a reminder message one day prior to and the day of the webinar.
Please be sure to register today!
Save 6% now on MenQuadfi® Meningococcal Group A, C, W and Y Conjugate Vaccine
Sanofi is offering a 6% sales promotion on all MenQuadfi® Meningococcal Group A, C, W and Y Conjugate Vaccine orders placed between February 5, 2024 and March 31, 2024. You can schedule MenQuadfi® orders to ship immediately or future ship through October 31, 2024 on VaccineShop.com or VaxServe.com. Scheduling orders now can help you manage your inventory throughout the back-to-school season.
If you have any additional questions, please feel free to contact a Sanofi representative or call Sanofi’s customer service at 1-800-822-2463.
Don’t Delay! Sanofi Price Increase
There is still time to lock into your 2023 Sanofi Vaccine Membership Pricing...
Please note that Sanofi prices increase on their Vaccines, effective January 1, 2024. Contact Tina Clark, our PRN Contract Administrator, if you need assistance at tina@prn-gpo.com.
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
On July 17, 2023, The U.S. Food and Drug Administration (FDA) approved Beyfortus™, a long-acting antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in all infants born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Here is the full press release with additional information.